Melanoma caught early is one of the most curable cancers. When it’s still confined to the skin where it started, the five-year survival rate is over 99%. Once it spreads to nearby lymph nodes, that drops to 76%, and if it reaches distant organs, it falls to about 35%. The single biggest factor in whether melanoma is curable is how deep it has grown and how far it has traveled before it’s found.
Stage 0 and Early Melanoma
Melanoma in situ, sometimes called stage 0, sits entirely in the top layer of skin and hasn’t invaded deeper tissue. Surgery removes it with a margin of healthy skin around the edges, and for most people that’s the end of treatment. Current guidelines recommend a 5 mm margin, but research shows that’s not always enough, particularly on the head and neck. A 10-year review of head and neck cases found only 62% were fully cleared with 5 mm margins, and margins of 15 mm were needed to reach a 97% clearance rate. For melanomas on the trunk or limbs, standard margins tend to be more reliable.
Once you move into stage I, the melanoma has started to grow into the second layer of skin but remains thin, typically 1 mm or less. The five-year survival here is still extremely high. After surgical removal, many stage I patients need only brief follow-up: appointments every six months for about a year, with no routine scans. If nothing turns up, ongoing monitoring usually isn’t needed.
Why Thickness Matters More Than Almost Anything
The single most important measurement in a melanoma diagnosis is Breslow depth, which is how far the tumor extends downward into the skin, measured in millimeters. Thinner melanomas are far less likely to have sent cancer cells elsewhere. Tumors less than 1 mm thick carry an excellent prognosis. Between 1 and 2 mm, the risk starts to climb. Between 2 and 4 mm, outcomes become more uncertain. And melanomas thicker than 4 mm carry the highest risk of spreading.
Ulceration, meaning the skin over the melanoma has broken down, also worsens the outlook at every thickness level. A 2 mm melanoma with ulceration is staged higher and carries a worse prognosis than a 2 mm melanoma without it. Interestingly, the primary tumor’s characteristics can matter more than whether cancer has reached a nearby lymph node. Patients with thick, ulcerated melanomas that haven’t yet reached the lymph nodes (stage IIB/C) have similar survival rates to patients with thinner melanomas that have reached one or two nodes (stage IIIA/B). The tumor itself tells much of the story.
Regional Spread: Still Treatable
When melanoma reaches nearby lymph nodes or skin, the five-year survival rate is 76%. This is a meaningful drop from localized disease, but it’s far from a death sentence. Treatment typically involves surgery to remove the affected nodes, often followed by additional therapy to reduce the chance of recurrence.
Follow-up becomes more intensive at this stage. Appointments are more frequent, scans may be part of the routine, and the monitoring window extends for years. The risk of recurrence is real, but many patients with regional disease are successfully treated and remain cancer-free long term.
Advanced Melanoma and the Immunotherapy Shift
Metastatic melanoma, where cancer has spread to distant organs like the lungs, liver, or brain, was once considered nearly untreatable. Before 2011, the five-year survival rate for stage IV melanoma was in the single digits. That picture has changed dramatically.
The introduction of checkpoint inhibitors, drugs that help the immune system recognize and attack cancer cells, transformed outcomes. In the landmark CheckMate 067 trial of previously untreated advanced melanoma patients, combination immunotherapy produced a five-year overall survival rate of 52%. Single-agent immunotherapy achieved 44%. Before these drugs existed, the older immunotherapy option managed just 26% at five years. For some patients, the median overall survival on combination therapy exceeded five years, a figure that would have been unthinkable a generation ago.
These treatments work by releasing the brakes on the immune system, and when they work well, responses can be durable, lasting years without additional treatment. The trade-off is side effects. Combination immunotherapy caused serious side effects in 59% of patients in the trial, compared to 22% for the single-agent approach. These can include inflammation in the gut, liver, lungs, or hormone-producing glands, and they require careful management.
Targeted Therapy for Specific Mutations
About 40 to 50% of melanomas carry a specific genetic mutation called BRAF V600. For these patients, targeted drugs that block the signals driving cancer growth offer another treatment path. The most effective approach combines two types of these drugs, which together produce response rates around 63 to 70% and median overall survival ranging from roughly 25 to 34 months depending on the specific combination.
The best-performing combination in clinical trials achieved a median progression-free survival of nearly 15 months and median overall survival of about 34 months. These numbers are lower than those for immunotherapy in some patients, but targeted therapy tends to work faster and can be especially valuable when rapid tumor shrinkage is needed. For patients whose melanomas carry the BRAF mutation, immunotherapy showed a particularly strong advantage with combination treatment: five-year survival of 60% compared to 46% with single-agent immunotherapy.
What Affects Your Individual Outlook
Population-level survival statistics are useful benchmarks, but individual outcomes vary. The factors that matter most include:
- Tumor thickness at diagnosis: Thinner melanomas have dramatically better outcomes.
- Ulceration: Its presence worsens prognosis at every stage.
- Location of spread: Melanoma that has reached only nearby skin or a single lymph node behaves very differently from melanoma in the brain or liver.
- Mutation status: BRAF-mutant melanomas respond well to both targeted therapy and combination immunotherapy. Mucosal melanomas, a rarer subtype, showed a five-year survival of 36% on combination immunotherapy versus 17% on single-agent treatment.
- Response to treatment: Patients who achieve a complete response to immunotherapy often maintain that response for years.
Life After Treatment
For early-stage melanoma, follow-up is relatively light. Stage 0 patients typically need just one post-treatment visit. Stage IA patients are usually seen every six months for a year, then discharged if everything looks clear. Higher-risk patients are monitored more closely, with schedules tailored to their specific situation, including factors like pregnancy, inability to have a lymph node biopsy, or elevated risk of developing a second melanoma.
For more advanced stages, follow-up stretches over several years and may include regular imaging. Recurrence is most common in the first two to three years but can happen later, which is why long-term skin checks remain important even after the formal surveillance window closes. People who’ve had one melanoma are also at higher risk of developing a new, unrelated melanoma, making ongoing skin awareness a lifelong habit worth maintaining.